TY - JOUR
T1 - Prediction of contrast-induced nephropathy by the serum creatinine level on the day following cardiac catheterization
AU - CINC-J study investigators
AU - Watanabe, Makoto
AU - Saito, Yoshihiko
AU - Aonuma, Kazutaka
AU - Hirayama, Atsushi
AU - Tamaki, Nagara
AU - Tsutsui, Hiroyuki
AU - Murohara, Toyoaki
AU - Ogawa, Hisao
AU - Akasaka, Takashi
AU - Yoshimura, Michihiro
AU - Sato, Akira
AU - Takayama, Tadateru
AU - Sakakibara, Mamoru
AU - Suzuki, Susumu
AU - Ishigami, Kenichi
AU - Onoue, Kenji
N1 - Funding Information:
This study was supported by grants from the Japanese Ministry of Education, Culture, Sports, Science and Technology and the Takeda Science Foundation .
Funding Information:
Hisao Ogawa received a research grant from AstraZeneca KK, Daiichi Sankyo Company, MSD KK, Pfizer Inc., Sanofi KK, Takeda Pharmaceutical Company, Astellas Pharma Inc., Boehringer Ingelheim Co., Ltd., Bristol-Myers Squibb, Dainippon Sumitomo Pharma Co., Ltd., Kowa Pharmaceutical Co., Ltd., Novartis Pharma KK, Bayer Pharmaceutical Co., Chugai Pharmaceutical Co., Ltd., and Otsuka Pharmaceutical Co., Ltd., and received honoraria for writing promotional material for AstraZeneca KK, Bayer Pharmaceutical Co., Pfizer Inc., Sanofi KK, Takeda Pharmaceutical Co., Daiichi Sankyo Company, and MSD KK.
Funding Information:
Nagara Tamaki received a research grant from Hitachi, Ltd., Nihon Medi-Physics Co., Ltd., Smoking Research Foundation, and Shionogi & Co., Ltd., has scholarship funds or donations from Nihon Medi-Physics Co., Ltd., and Shionogi & Co., Ltd., and has endowed departments by commercial entities, Shionogi & Co., Ltd.
Funding Information:
Atsushi Hirayama received a research grant from Shionogi Pharmaceutical Co., Chugai Pharmaceutical Co., Novartis Pharma KK, Goodman Co., Ltd., Zeon Medical Inc., Dainippon Sumitomo Pharma Co., Ltd., Medtronic Japan Co., Ltd., Mochida Pharmaceutical Co., Ltd., Astellas Pharma Inc., Daiichi-Sankyo Pharmaceutical Co., Sanofi KK, Nippon Boehringer Ingelheim Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kowa Co., Ltd., Kissei Pharmaceutical Co., Ltd., MSD, Eisai Co., Ltd., Pfizer Japan, Otsuka Pharmaceutical Co., Tanabe Mitsubishi Pharmaceutical Co., AstraZeneca Co., and Nihon Medi-Physics Co., Ltd., and received honoraria for writing promotional material for Astellas Pharma Inc., Daiichi-Sankyo Pharmaceutical Co., Sanofi KK, Kyowa Hakko Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Kowa Co., Ltd.
Funding Information:
Yoshihiko Saito received a research grant from MSD Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and Daiichi Sankyo Company Ltd., received honoraria for writing promotional material for MSD Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Company Ltd., Otsuka Pharmaceutical Co., Ltd., and Pfizer Japan Inc., and has endowed departments by commercial entities, MSD Co., Ltd.
Publisher Copyright:
© 2016
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Background The majority of patients who undergo coronary arteriography are discharged from the hospital on the day of the procedure or on the following day. The aim of this study is to investigate whether the change in serum creatinine (SCr) and estimated glomerular filtration rate (eGFR) on the day following cardiac catheterization can predict the development of contrast-induced nephropathy (CIN). Methods This is a multicenter prospective observational study, which consists of 860 patients who underwent cardiac catheterization. We measured SCr and eGFR before cardiac catheterization, on the following day, and 48–72 h post-procedure. Definition of CIN is changes in SCr ≥0.5 mg/dL or ≥25% from baseline 48–72 h after contrast exposure. Results CIN occurred in 40 patients. SCr levels significantly increased from a baseline of 1.55 ± 1.08 mg/dL to 1.79 ± 1.26 mg/dL on the following day in patients with CIN (p < 0.0001), but significantly decreased from a baseline of 1.21 ± 0.65 mg/dL to 1.18 ± 0.61 mg/dL on the following day in those without CIN (p < 0.0001). eGFR significantly decreased from a baseline of 47.3 ± 28.3 mL/min/1.73 m2 to 40.6 ± 26.7 mL/min/1.73 m2 on the following day in patients with CIN (p < 0.0001), but significantly increased from a baseline of 53.1 ± 22.0 mg/dL to 53.6 ± 21.2 mg/dL on the following day in those without CIN (p = 0.0236). Receiver operating characteristic curve analysis indicated that SCr change ≥0.1 mg/dL [area under the curve (AUC) = 0.852, sensitivity 72.5%, specificity 86.1%] and eGFR change ≤−1.1 mL/min/1.73 m2 (AUC = 0.789, sensitivity 85.0%, specificity 64.9%) were the best cut-off values for predicting CIN. Multivariate logistic regression showed that a change in SCr ≥0.1 mg/dL [odds ratio (OR), 29.3; 95% confidence interval (CI), 10.8–96.2] and change in eGFR ≤−1.1 mL/min/1.73 m2 (OR, 69.7; 95% CI, 13.3–952) were powerful independent predictors of CIN. Conclusions Changes in SCr and eGFR on the day following cardiac catheterization predict the development of CIN.
AB - Background The majority of patients who undergo coronary arteriography are discharged from the hospital on the day of the procedure or on the following day. The aim of this study is to investigate whether the change in serum creatinine (SCr) and estimated glomerular filtration rate (eGFR) on the day following cardiac catheterization can predict the development of contrast-induced nephropathy (CIN). Methods This is a multicenter prospective observational study, which consists of 860 patients who underwent cardiac catheterization. We measured SCr and eGFR before cardiac catheterization, on the following day, and 48–72 h post-procedure. Definition of CIN is changes in SCr ≥0.5 mg/dL or ≥25% from baseline 48–72 h after contrast exposure. Results CIN occurred in 40 patients. SCr levels significantly increased from a baseline of 1.55 ± 1.08 mg/dL to 1.79 ± 1.26 mg/dL on the following day in patients with CIN (p < 0.0001), but significantly decreased from a baseline of 1.21 ± 0.65 mg/dL to 1.18 ± 0.61 mg/dL on the following day in those without CIN (p < 0.0001). eGFR significantly decreased from a baseline of 47.3 ± 28.3 mL/min/1.73 m2 to 40.6 ± 26.7 mL/min/1.73 m2 on the following day in patients with CIN (p < 0.0001), but significantly increased from a baseline of 53.1 ± 22.0 mg/dL to 53.6 ± 21.2 mg/dL on the following day in those without CIN (p = 0.0236). Receiver operating characteristic curve analysis indicated that SCr change ≥0.1 mg/dL [area under the curve (AUC) = 0.852, sensitivity 72.5%, specificity 86.1%] and eGFR change ≤−1.1 mL/min/1.73 m2 (AUC = 0.789, sensitivity 85.0%, specificity 64.9%) were the best cut-off values for predicting CIN. Multivariate logistic regression showed that a change in SCr ≥0.1 mg/dL [odds ratio (OR), 29.3; 95% confidence interval (CI), 10.8–96.2] and change in eGFR ≤−1.1 mL/min/1.73 m2 (OR, 69.7; 95% CI, 13.3–952) were powerful independent predictors of CIN. Conclusions Changes in SCr and eGFR on the day following cardiac catheterization predict the development of CIN.
UR - http://www.scopus.com/inward/record.url?scp=84950145935&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84950145935&partnerID=8YFLogxK
U2 - 10.1016/j.jjcc.2015.10.016
DO - 10.1016/j.jjcc.2015.10.016
M3 - Article
C2 - 26708123
AN - SCOPUS:84950145935
SN - 0914-5087
VL - 68
SP - 412
EP - 418
JO - Journal of Cardiology
JF - Journal of Cardiology
IS - 5
ER -